[Predictable toxicities with futures immunotherapies or combinations].

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Immune checkpoint inhibitors (ICIs) have significantly improved survival in various solid tumors by enhancing anti-tumor immunity.
• While effective, ICIs can lead to immune-related adverse events (IRAEs), which are sometimes severe and can compromise treatment.
• The development of new immunotherapies and combination therapies necessitates a thorough understanding of their safety profiles.

Purpose of the Study:

• To review the safety profile of immune checkpoint inhibitors (ICIs) in clinical practice.
• To highlight the occurrence and management of immune-related adverse events (IRAEs) associated with ICIs.
• To emphasize the importance of safety and quality of life as key endpoints in long-term cancer treatment decisions.

Main Methods:

• Review of clinical practice data and safety profiles of immune checkpoint inhibitors (ICIs).
• Analysis of immune-related adverse events (IRAEs) in patients treated with ICIs.
• Discussion of emerging immunotherapies and combination strategies.

Main Results:

• Immune checkpoint inhibitors (ICIs) demonstrate improved survival outcomes for numerous solid tumors.
• Immune-related adverse events (IRAEs) are a known class of toxicity, occurring less frequently than chemotherapy side effects but potentially serious.
• Management of IRAEs is critical for maintaining treatment continuity and improving patient quality of life.

Conclusions:

• Effective management of immune-related adverse events (IRAEs) is essential for optimizing the use of immune checkpoint inhibitors (ICIs) in cancer therapy.
• As novel immunotherapies and combinations are developed, understanding and managing their unique safety profiles will be paramount.
• Long-term treatment efficacy, safety, and patient quality of life are becoming critical factors in therapeutic decision-making for advanced cancers.